Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Expected to Rise, JMP Securities Analyst Says

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) had its price objective lifted by analysts at JMP Securities from $23.00 to $24.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a "market outperform" rating on the biotechnology company's stock. JMP Securities' target price indicates a potential upside of 221.29% from the company's current price.

Several other equities research analysts have also recently commented on the company. Wall Street Zen raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 19th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $18.00.

Enanta Pharmaceuticals Price Performance

ENTA traded up $0.26 during trading hours on Tuesday, hitting $7.47. 118,893 shares of the stock were exchanged, compared to its average volume of 285,504. The stock has a 50-day simple moving average of $5.53 and a 200-day simple moving average of $6.20. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $17.24. The stock has a market cap of $159.69 million, a price-to-earnings ratio of -1.51 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. The company had revenue of $14.93 million for the quarter, compared to analyst estimates of $15.96 million. Sell-side analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Institutional Trading of Enanta Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. AlphaQuest LLC increased its holdings in Enanta Pharmaceuticals by 16.4% in the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock worth $128,000 after purchasing an additional 3,137 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Enanta Pharmaceuticals by 51.3% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 290,011 shares of the biotechnology company's stock worth $1,668,000 after acquiring an additional 98,285 shares in the last quarter. Thrivent Financial for Lutherans bought a new position in Enanta Pharmaceuticals in the fourth quarter worth approximately $254,000. Millennium Management LLC raised its stake in shares of Enanta Pharmaceuticals by 22.7% in the fourth quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company's stock worth $5,158,000 after purchasing an additional 165,692 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of Enanta Pharmaceuticals by 9.3% in the fourth quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company's stock worth $5,348,000 after purchasing an additional 79,197 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.